LGD-2226

LGD-2226 functions as a selective androgen receptor agonist that binds AR and modulates gene transcription programs involved in muscle protein synthesis, bone remodeling, and anabolic signaling. Mechanistic framing commonly includes:​

• Preferential activation of AR in skeletal muscle and bone models with comparatively reduced stimulation of prostate-related androgen-sensitive tissues in preclinical designs.​
• Effects on muscle protein balance signaling and structural integrity, including pathways associated with hypertrophy and resistance to catabolic stressors.​
• Tissue “selectivity” patterns that vary with dose, exposure duration, background androgen status, and model species.​
• Modulation of bone density and structural integrity proxies via AR-mediated effects on osteoblastic and osteoclastic signaling cascades.​
• Strong dependence on formulation, stability, and verified identity, as vehicle choice and storage conditions can materially alter exposure and observed pharmacodynamic outcomes.​

LGD-2226 is commonly studied in laboratory research related to

• Androgen receptor signaling pathways and comparative profiling versus other SARM and steroidal ligands.​
• Skeletal muscle growth, maintenance, and disuse or atrophy models under defined dietary and activity conditions.​
• Bone density and structural integrity research where AR modulation is probed as a driver of bone anabolic responses.​
• Structure–activity relationship and SARM development programs focused on maximizing tissue-selective anabolic signaling.​
• Integrated muscle–bone axis models exploring coordination of AR-driven changes across connected tissues.​

Reported observations with AR-active research compounds vary by model, dose, and exposure strategy and may include

• Suppression of endogenous gonadotropin signaling and related androgen markers in some in vivo systems where AR feedback is engaged.
• Lipid marker changes (e.g., HDL, LDL, triglycerides) under sustained exposure in metabolic and cardiovascular-adjacent research designs.
• Liver enzyme alterations in certain protocols, particularly at higher doses, longer durations, or in combination with interacting agents.
• Androgenic-type effects in accessory androgen-sensitive tissues when tissue selectivity is exceeded or in susceptible models.
• Withdrawal or rebound patterns in endocrine markers and structural proxies after discontinuation, emphasizing the importance of washout and follow-up windows in study design.

Model controls matter: Stacking confounders: Form factor differences: Identity and verification: Endpoints to predefine

• Diet composition, training or loading stimulus, baseline androgen status, and sleep or circadian conditions can strongly influence lean mass, bone metrics, and endocrine outcomes and should be standardized.
• Background stressors, comorbid experimental manipulations, and housing or environmental factors can meaningfully confound AR-related interpretations.
• Pairing LGD-2226 with other AR-active agents (SARMs, anabolic steroids, prohormones) can obscure attribution and amplify endocrine suppression signals.
• Adding strong stimulants, thyroid-active agents, glucocorticoids, or aggressive caloric manipulation can dominate metabolic and performance readouts and mask the specific contribution of selective AR modulation.
• Powder versus liquid formulations can yield different absorption and exposure curves depending on vehicle, route, and preparation technique.​
• Co-solvents and carriers such as PEG-400 and DMSO should be documented and mirrored in vehicle control arms where feasible to separate vehicle from active-compound effects.​
• Analytical confirmation (COA review, third-party testing where possible, and internal stability checks) is important to ensure that LGD-2226 identity, purity, and concentration match protocol assumptions.​
• Researchers should record CAS number (328947-93-9), IUPAC name, molecular formula (C₁₄H₉F₉N₂O), and molecular weight (392.225 g/mol), and ensure dose calculations align with these properties.​
• Lean mass, muscle strength or performance proxies, bone density/structure metrics, and AR-related endocrine markers should be specified prior to exposure to minimize bias.
• Lipids, liver enzymes, and other safety-relevant laboratories, along with recovery and washout endpoints, should be built into the protocol before initiation of dosing.